CardiAQ Gets $37.3M For Heart Valve Replacement

Irvine-based CardiAQ, which is developing medical devices used in percutaneous mitral heart valve replacement, said this morning that it has raised $37.3M in a Series B funding round. The funding was led by Orbimed, and also included Versant Ventures, Advent Life Sciences, and the firm's existing investors. CardiAQ said the funding will go towards validating its technology and towards feasibility and CE mark clinical trials. Orbimed's David Bonita and Vince Burgess join the company's board with the funding. More information »